Drugs / Pembrolizumab (US)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06311721 | Sep 2024 → Jan 2028 expected | non-small cell lung carcinoma | Amgen | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pembrolizumab (US) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06311721 ↗ |
| Route | Intravenous | “Intravenous administration” NCT06311721 ↗ |